Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
April 18, 2019 08:00 ET
|
Resverlogix Corp
CALGARY, Alberta, April 18, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announces that BETonMACE, the Company’s event-based, phase 3 registration...
Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone
December 19, 2018 08:30 ET
|
Resverlogix Corp
CALGARY, Alberta, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announces the independent Data and Safety Monitoring Board (DSMB) has completed...
Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610 in Myelofibrosis
October 10, 2018 16:30 ET
|
Constellation Pharmaceuticals , Inc.
– Amends second-line trial design to stratify for transfusion dependence based on positive preliminary data – – Expands study to include an additional arm evaluating CPI-0610 as first-line therapy in...
Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2018 Financial Results
August 14, 2018 16:15 ET
|
Constellation Pharmaceuticals , Inc.
Company raises an aggregate of $160 million in crossover financing in April and initial public offering (IPO) in JulyCompany progressing its pipeline, including clinical programs CPI-1205 and CPI-0610...
Constellation Pharmaceuticals Announces Pricing of Initial Public Offering
July 18, 2018 19:56 ET
|
Constellation Pharmaceuticals , Inc.
CAMBRIDGE, Mass., July 18, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (the “Company”)(Nasdaq:CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to...